Skip to content

3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension

3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02799979
Acronym
HTP3S
Enrollment
150
Registered
2016-06-15
Start date
2014-10-10
Completion date
2022-02-02
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Brief summary

Pulmonary hypertension is a rare and severe disease, affecting a young population. Survival is very poor and has been closely related to right ventricular dysfunction. Current prognostic equations rely mostly on right heart catheterization data. The identification of simple echocardiographic prognostic factor is urgently needed. It could help identifying with a non invasive method, high risk patients who could benefit from an intensive specific therapy. 3D right ventricular imaging is a new echocardiographic tool which provides RV volumic analysis, RV ejection fraction, overcoming the classical limits of 2D ultrasound. The aim of this study is to validate a new software for 3D analysis of the right ventricle and assess its prognostic role in pulmonary hypertension. To do so, the investigators will realize a prospective monocentric longitudinal cohort study, including 100 pulmonary hypertension patients. Echocardiographic data will be collected at baseline and after 6 months.

Interventions

DEVICE3D right ventricular imaging echocardiographic

Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients \> 18 years old * Pulmonary hypertension diagnosed by right heart catheterization * Informed consent obtained * Affiliation to the French national health insurance

Exclusion criteria

* Associated significant left heart disease * Sub-optimal acoustic windows * Patient unable to attend follow-up visits

Design outcomes

Primary

MeasureTime frameDescription
Number of death from any causeBaseline to 24 monthsDescription of the number of death during the study

Secondary

MeasureTime frameDescription
Number of HospitalisationBaseline to 24 monthsDescription of the number of hospitalisation for worsening of pulmonary arterial hypertension
3D right ventricular imaging echocardiographicBaseline and 6 monthsAnalyse the data of 3D right ventricular (RV), ejection fraction, RV telediastolic and telesystolic volume, 3D RV area strain (%)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORPAMELA MOCERI, MD

Centre Hospitalier Universitaire de Nice

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026